Lexicon Pharma (LXRX) Reports In-Line Q1 Loss of 4c/Share
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.02 -6.05%
Revenue Growth %: -78.9%
Financial Fact:
Total revenues: 27.72M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -78.9%
Financial Fact:
Total revenues: 27.72M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q1 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $1.8 million versus the consensus estimate of $1.1 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- Morgan Stanley Reiterates Overweight Rating on Kingspan Group PLC (KSP:ID), Adds to Top Picks
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
